BRAF mutation

From Libre Pathology
Revision as of 18:15, 23 January 2019 by Michael (talk | contribs)
Jump to navigation Jump to search

BRAF mutation is a common genetic change in cancer.

General

  • BRAF inhibitors (e.g. vemurafenib) is used to treat BRAF mutation positive tumours.[1]

Prevalence by tumour type:[1]

  • BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
  • BRAF mutations in ~ 10% of colorectal tumours.
    • Poor prognosticator, poor response to chemotherapy, typically right sided tumours.
  • BRAF mutations in ~45-50% of papillary thyroid carcinoma.
  • BRAF mutations in ~3% of lung adenocarcinomas.

References

  1. ↑ 1.0 1.1 Cheng, L.; Lopez-Beltran, A.; Massari, F.; MacLennan, GT.; Montironi, R. (01 2018). "Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.". Mod Pathol 31 (1): 24-38. doi:10.1038/modpathol.2017.104. PMID 29148538.
Retrieved from "https://librepathology.org/w/index.php?title=BRAF_mutation&oldid=49728"